证券代码：603367 证券简称：辰欣药业 公告编号：2024-039 辰欣药业股份有限公司 关于持股 5%以上股东集中竞价减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 大股东持股的基本情况 截至本次减持计划披露之日，辰欣药业股份有限公司（以下简称"公司"或 "辰欣药业"）持股 5%以上股东北海辰昕创业投资有限公司（以下简称"北海辰 昕"）持有辰欣药业无限售流通股份 46,782,021 股，占辰欣药业总股本的 10.33%。 上述股份来源均为公司首次公开发行前股份，且已与 2018 年 10 月 11 日全部解 除限售并上市流通。 集中竞价减持计划的主要内容 自本公告披露之日起满 15 个交易日后的 3 个月内，北海辰昕拟通过集中竞 价交易方式合计减持数量不超过 4,527,751 股，不超过公司总股本的 1%。在任 意连续 90 日内，减持股份的总数不超过公司股份总数的 1%。在上述减持计划实 施期间，公司发生派发红利、送红股、转增股本、增发新股或配股等股本变动股 本除权、除息 ...

关于辰欣药业股份有限公司实际控制人、董事长 兼总经理增持公司股份的专项核查意见 北京市盈科（济南）律师事务所 济南市历下区经十路11111号济南华润中心39层 郎编：250014 电话： (86)0531-55698000 传真： (86) 0531-5569811 北京市盈科（济南）律师事务所 7 北京市盈科 (济南) 律师事务所 关于辰欣药业股份有限公司实际控制人、董事长 兼总经理增持公司股份的专项核查意见 【2024】盈济南非诉字第 JN 号 致: 辰欣药业股份有限公司 北京市盈科(济南)律师事务所(以下简称"本所")接受辰欣药业股份有 限公司（以下简称"公司"、"辰欣药业"）委托，根据《中华人民共和国公司 法》（以下简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证 券法》"）《上海证券交易所股票上市规则》（以下简称"《上市规则》"） 《上市公司收购管理办法》（以下简称"《收购管理办法》"）《上海证券交易 所上市公司自律监管指引第 8 号 -- 股份变动管理》(以下简称"《8 号指 引》"） 等有关法律、行政法规、部门规章、规范性文件以及《辰欣药业股份 有限公司章程》的有关规定，就辰欣药业实 ...

辰欣药业股份有限公司 证券代码：603367 证券简称：辰欣药业 公告编号：2024-037 关于实际控制人、董事长兼总经理增持股份 计划实施完毕暨增持结果的公告 本次增持计划实施结果：截至本公告披露日，杜振新先生已通过上海证券交 易所交易系统以集中竞价交易方式合计增持公司股份 1,875,100 股，占公司总股 本的 0.41%，合计增持金额为人民币 21,891,097.28 元，增持金额超过本次增持 计划的区间下限，本次增持计划已实施完毕。 公司于 2024 年 5 月 6 日收到杜振新先生《关于增持公司股份计划实施完毕 暨增持结果的告知函》，现将相关情况公告如下： 一、增持主体的基本情况 1、增持主体：辰欣药业实际控制人、董事长兼总经理杜振新先生 2、增持主体本次增持前持股情况： 本次增持前，杜振新先生及一致行动人辰欣科技集团有限公司、北海辰昕创 业投资有限公司、卢秀莲女士合计持有辰欣药业 167,437,100 股份，占公司总股 本的比例为 36.98%。其中，杜振新先生直接持有辰欣药业 1,763,900 股股份， 1 / 3 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或 ...

Investment Rating - The investment rating for the company is "Buy-A" with a target price of 21.42 CNY for the next 6 months [1][12]. Core Insights - The company is expected to benefit from the recovery in demand for large-volume infusion products and continuous expansion of new products, leading to steady growth [11]. - The overall gross margin for the company improved to 58.79% in 2023, an increase of 2.80 percentage points year-on-year [11]. - The company’s revenue and net profit for Q1 2024 were 1.149 billion CNY and 163 million CNY, respectively, representing year-on-year growth of 1.28% and 4.50% [11]. Financial Performance - The company is projected to achieve revenues of 4.956 billion CNY, 5.437 billion CNY, and 5.868 billion CNY for 2024, 2025, and 2026, respectively, with year-on-year growth rates of 11.06%, 9.69%, and 7.94% [25]. - The expected net profits for 2024, 2025, and 2026 are 573 million CNY, 623 million CNY, and 674 million CNY, with growth rates of 9.8%, 8.7%, and 8.3% [12][25]. - The earnings per share (EPS) for 2024 is estimated to be 1.26 CNY, with a price-to-earnings (PE) ratio of 17 times [12][32]. Market Position and Industry Outlook - The large-volume infusion industry has seen an improvement in supply-demand dynamics, which is expected to enhance the company's profitability [5][11]. - The company has successfully bid for several new products in the eighth batch of centralized procurement, which is anticipated to drive rapid sales growth [11]. - The overall market for medical institutions is recovering, with the total number of medical visits in China increasing from 460 million in January 2023 to 602 million in August 2023 [11].

Financial Performance - The company's operating revenue for 2023 reached ¥4,462,348,636.07, representing a year-on-year increase of 9.75% compared to ¥4,066,088,448.57 in 2022 [23]. - Net profit attributable to shareholders was ¥521,338,330.89, a significant increase of 48.97% from ¥349,958,583.46 in the previous year [23]. - The basic earnings per share for 2023 was ¥1.15, up 49.35% from ¥0.77 in 2022 [25]. - The weighted average return on equity increased to 9.49%, up 2.73 percentage points from 6.76% in 2022 [25]. - The net cash flow from operating activities was ¥451,240,761.60, reflecting a 74.67% increase from ¥258,345,605.17 in 2022 [23]. - Total assets at the end of 2023 amounted to ¥7,337,838,152.94, a 7.67% increase from ¥6,815,073,080.14 at the end of 2022 [24]. - The company's net assets attributable to shareholders increased by 7.41% to ¥5,727,355,807.20 from ¥5,332,181,340.75 in 2022 [24]. - The total profit for 2023 was 596 million RMB, an increase of 62.72% compared to the previous year [33]. - The net profit attributable to the parent company was 521 million RMB, reflecting a growth of 48.97% year-on-year [33]. - The net profit excluding non-recurring gains and losses was 451 million RMB, up 36.21% from the previous year [33]. Dividend Distribution - The company plans to distribute a cash dividend of 4.36 RMB per 10 shares, totaling approximately 197.41 million RMB based on the distribution plan [6]. - The company has a total of 452,764,629 shares eligible for dividend distribution, excluding 10,500 shares pending repurchase [6]. - The total cash dividend amount distributed was RMB 197,405,378.24, which represents 37.87% of the net profit attributable to ordinary shareholders in the consolidated financial statements [181]. - The company maintains a continuous and stable profit distribution policy, considering both investor returns and long-term development needs [175]. - The profit distribution plan was approved by the shareholders' meeting, ensuring the protection of minority shareholders' rights [175]. Research and Development - The company has increased its R&D investment, focusing on quality control and clinical value optimization [36]. - R&D investment accounts for over 8% of the company's revenue, supporting sustainable development and transformation [57]. - The company has over 100 ongoing R&D projects focused on complex injection agents, controlled-release oral solid preparations, and new drugs for major clinical needs [90]. - The company is committed to research and development of innovative therapies for chronic diseases, including hepatitis and cardiovascular conditions [84]. - The company is actively pursuing new drug development in areas such as anti-infection and diabetes management [98]. Market Strategy and Expansion - The company plans to continue expanding its market presence and investing in new product development to sustain growth in the coming years [23]. - The company is actively expanding its market presence in OTC drugs, special medical foods, and traditional Chinese medicine products [34]. - The company is focusing on expanding its market presence through strategic acquisitions and partnerships in the pharmaceutical sector [86]. - The company is enhancing its CRM system and budget management to strengthen market and business management functions [34]. - The company is adapting its business strategies in response to regulatory changes in the pharmaceutical industry, aiming to accelerate product approvals and market entry [51]. Compliance and Governance - The company has established a comprehensive internal control governance structure to maintain independence from its actual controllers [134]. - The company adheres to strict information disclosure practices, ensuring transparency and equal access to information for all shareholders [134]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with governance regulations [133]. - The company has established specialized committees within the board, including an audit committee, nomination committee, compensation and assessment committee, and strategic committee [155]. - The company emphasizes maintaining independence and operational capability during the spin-off process [151]. Environmental Responsibility - The company invested 20.34 million yuan in environmental protection during the reporting period [191]. - The company has installed activated carbon treatment equipment to ensure that emissions meet standards, with regular third-party disposal of hazardous waste [194]. - The company has undergone multiple environmental impact assessments for various projects, including a production capacity of 30 million soft-pack intravenous solutions annually [195]. - The company has not experienced any environmental incidents during the reporting period [199]. - The actual concentration of COD was 41.75 mg/L, significantly below the limit of 500 mg/L [200]. Risks and Challenges - The company faces risks from intensified market competition, with potential threats from competitors launching more effective or cost-effective products [127]. - Raw material price fluctuations can adversely affect production costs and profitability, prompting the company to implement a procurement strategy to manage these risks [129]. - The pharmaceutical manufacturing industry is significantly impacted by policy changes, including revisions to drug management laws and adjustments to medical insurance catalogs [127]. - Environmental regulations pose risks to production operations, necessitating the establishment of an environmental management department to enhance operational capabilities [129]. - In 2023, the pharmaceutical industry in China is expected to face significant challenges due to rising costs in research, labor, and production, alongside intensified competition and regulatory scrutiny [41].

Financial Performance - The company's revenue for Q1 2024 was CNY 1,148,946,834.25, representing a year-on-year increase of 1.28%[6] - Net profit attributable to shareholders was CNY 162,863,217.96, reflecting a growth of 4.50% compared to the same period last year[6] - Total operating revenue for Q1 2024 was approximately ¥1.15 billion, a slight increase of 1.5% compared to ¥1.13 billion in Q1 2023[24] - Net profit for Q1 2024 reached approximately ¥162.18 million, representing an increase of 3.1% from ¥157.21 million in Q1 2023[25] - Operating profit for Q1 2024 was ¥142,970,237.88, down 13.0% from ¥164,118,173.52 in Q1 2023[32] - Net profit for Q1 2024 was ¥129,419,933.08, a decline of 13.0% compared to ¥148,665,145.47 in Q1 2023[32] Cash Flow - The net cash flow from operating activities increased significantly by 145.25%, amounting to CNY 245,031,646.54[6] - Cash flow from operating activities generated a net inflow of approximately ¥245.03 million, compared to ¥99.91 million in Q1 2023, indicating a significant improvement[27] - Cash flow from operating activities generated a net amount of ¥182,959,351.08 in Q1 2024, compared to ¥98,805,509.39 in Q1 2023, indicating improved cash generation[35] - The cash flow from operating activities was not detailed, but the overall cash and cash equivalents decreased by $59.2 million[36] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 7,557,195,630.90, a 2.99% increase from the previous year[7] - The company's total current assets reached RMB 5,154,438,741.58, up from RMB 4,969,807,069.20, indicating an increase of about 3.7%[18] - The total liabilities of the company were RMB 1,617,622,267.54, compared to RMB 1,571,382,826.12, marking an increase of about 2.9%[20] - Total assets as of Q1 2024 were ¥6,774,469,544.92, an increase from ¥6,647,041,911.57 in Q1 2023[31] - Total liabilities for Q1 2024 were ¥1,417,009,755.18, slightly down from ¥1,419,002,054.91 in Q1 2023[31] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 21,273[13] - The largest shareholder, Chenxin Technology Group Co., Ltd., held 26.26% of the shares, amounting to 118,891,080 shares[14] - The company's equity attributable to shareholders was CNY 5,895,008,400.17, marking a 2.93% increase from the end of the previous year[7] - The company's total equity increased to ¥5,357,459,789.74 in Q1 2024, up from ¥5,228,039,856.66 in Q1 2023, reflecting a stronger financial position[31] Expenses - Total operating costs decreased to approximately ¥954.82 million, down 1.0% from ¥964.57 million in the same period last year[24] - Research and development expenses increased to ¥81,709,281.41 in Q1 2024, up from ¥77,150,126.75 in Q1 2023, reflecting a focus on innovation[32] - The company reported a tax expense of approximately ¥21.51 million for Q1 2024, an increase from ¥14.10 million in Q1 2023[25] - The company reported a decrease in sales expenses to ¥320,168,405.25 in Q1 2024 from ¥355,620,744.39 in Q1 2023, indicating cost management efforts[32] Other Income and Receivables - Other receivables increased by 149.35%, indicating a rise in business-related receivables during the reporting period[11] - The company reported a 517.56% increase in other income, primarily due to an increase in government subsidies recognized in the current period[11] Cash and Cash Equivalents - Cash and cash equivalents decreased to RMB 937,039,700.37 from RMB 983,389,232.24, a decline of approximately 4.7%[18] - Cash and cash equivalents at the end of Q1 2024 totaled approximately ¥937.04 million, a decrease from ¥983.39 million at the beginning of the quarter[28] - The ending cash and cash equivalents balance was $752.1 million, down from $759.7 million in the previous period[36] Investment Activities - Investment activities resulted in a net cash outflow of approximately ¥221.44 million in Q1 2024, compared to a net outflow of ¥186.14 million in Q1 2023[28] - The net cash flow from investment activities was -$234 million, compared to -$184 million in the previous period, indicating a decline in investment performance[36] - Total cash outflow for investment activities was $874.9 million, which is a decrease from $1.15 billion in the previous period[36] Accounting Standards - The company is implementing new accounting standards starting in 2024, which may affect future financial reporting[36]

证券代码：603367 证券简称：辰欣药业 公告编号：2024-032 辰欣药业股份有限公司关于 2023 年度 日常关联交易确认及 2024 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 辰欣药业股份有限公司（以下简称"公司"或"辰欣药业"）的日常关 联交易均属公司及下属子公司日常生产经营中的必要的业务，以市场公允价格为 定价标准，交易遵循公平、公正的市场原则，不会影响公司的独立性，公司的主 营业务不会因本次日常关联交易而对关联人形成依赖。 ●本次日常关联交易事项为董事会决策权限，无需提交股东大会审议。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 2024 年 4 月 22 日，公司召开第五届董事会第三次会议和第五届监事会第三 次会议，会议分别审议通过了《关于公司 2023 年度日常关联交易确认及 2024 年度日常关联交易预计的议案》，关联董事杜振新、郝留山、卢秀莲、续新兵、 黄保战回避了表决。本次关联交易事项为董事会决策权限，无需提交股东大会审 议。 公司 ...

辰欣药业股份有限公司 内控审计报告 大信审字[2024]第 3-00207 号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 大信会计师事务所 北京市海淀区知春路 1 号 学院国际大厦 22 层 2206 邮编 100083 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况的变化 可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控制审计结 果推测未来内部控制的有效性具有一定风险。 WUYIGE Certified Public Accountants.LLP Room 2206 22/F, Xueyuan International Tower No.1 Zhichun Road, Haidian Dist. Beijing,China,100083 电话 Telephone：+86（10）82330558 传真 Fax： +86（10）82327668 网址 Internet： www.daxincpa.com.cn 内部控制审计报告 大信审字[2024]第 3-00207 号 辰欣药业股份有限 ...

辰欣药业股份有限公司 募集资金存放与实际使用情况 审核报告 大信专审字[2024]第 3-00118 号 大信会计师事务所（特殊普通合伙） WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 大信会计师事务所 北京市海淀区知春路 1 号 学院国际大厦 22 层 2206 邮编 100083 WUYIGE Certified Public Accountants.LLP Room 2206 22/F, Xueyuan International Tower No.1 Zhichun Road, Haidian Dist. Beijing, China, 100083 电话 Telephone：+86（10）82330558 传真 Fax： +86（10）82327668 网址 Internet： www.daxincpa.com.cn 募集资金存放与实际使用情况审核报告 大信专审字[2024]第 3-00118 号 辰欣药业股份有限公司全体股东： 我们接受委托，对后附的辰欣药业股份有限公司（以下简称"贵公司"）《2023年度募 集资金存放与实际使用情况的专项报告》（以下简称"募集资 ...

证券代码：603367 证券简称：辰欣药业 公告编号：2024-028 辰欣药业股份有限公司 第五届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 辰欣药业股份有限公司（以下简称 "公司"或"辰欣药业"）第五届董事会第三 次会议于 2024 年 4 月 22 日在公司办公楼六楼会议室以现场结合通讯方式召开。本次 董事会会议通知于 2024 年 4 月 13 日以电子邮件、EM 系统、微信、电话等通讯方式发 出。会议应出席董事 9 名，实际出席会议董事 9 名。会议由董事长杜振新先生主持， 公司监事、其他高级管理人员列席会议。本次会议的召集和召开程序符合《公司法》 等相关法律法规及《公司章程》的有关规定，会议决议合法、有效。 二、董事会会议审议情况 经与会董事逐项审议，会议通过了如下议案： 1、审议通过《关于公司 2023 年度报告全文及其摘要的议案》 董事会审阅了公司编制的 2023 年年度报告全文及其摘要，认为可以全面、客观、 真实的反映公司 2023 年度经营情况。 ...